ES2190788T3 - Utilizacion de halogenuros aromaticos para tratar la proliferacion de celulas mamarias. - Google Patents

Utilizacion de halogenuros aromaticos para tratar la proliferacion de celulas mamarias.

Info

Publication number
ES2190788T3
ES2190788T3 ES95933137T ES95933137T ES2190788T3 ES 2190788 T3 ES2190788 T3 ES 2190788T3 ES 95933137 T ES95933137 T ES 95933137T ES 95933137 T ES95933137 T ES 95933137T ES 2190788 T3 ES2190788 T3 ES 2190788T3
Authority
ES
Spain
Prior art keywords
treatments
compounds
aromatic
proliferation
halogenures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933137T
Other languages
English (en)
Inventor
Jose Halperin
Carlo Brugnara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Harvard University
Original Assignee
Boston Children's Hospital
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital, Harvard University filed Critical Boston Children's Hospital
Application granted granted Critical
Publication of ES2190788T3 publication Critical patent/ES2190788T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA METODOS Y PRODUCTOS PARA INHIBIR LA PROLIFERACION CELULAR EN MAMIFEROS. LOS COMPUESTOS, QUE SON ANTIMICOTICOS Y QUE INHIBEN EL CANAL DE POTASIO ACTIVADO CA{SUP,++} DE LOS ERITROCITOS, SE HAN MODIFICADO PARA UTILIZARLOS EN LA PRESENTE INVENCION RETIRANDO EL GRUPO IMIDAZOL. ESTOS COMPUESTOS MODIFICADOS NORMALMENTE TIENEN AL MENOS GRUPOS AROMATICOS SEPARADOS UNOS DE OTROS PERO NO MAS DE CINCO ATOMOS, Y MAS NORMALMENTE NO MAS DE TRES ATOMOS. AL MENOS UNO DE LOS GRUPOS AROMATICOS SE SUSTITUYE CON UNA CLORINA U OTRA FUNCIONALIDAD CON UNA CARGA NEGATIVA NETA EN CONJUNTO. LOS COMPUESTOS PUEDEN UTILIZARSE EN CONEXION CON, ENTRE OTROS, TRATAMIENTOS PARA EL CANCER, TRATAMIENTOS PARA AFECCIONES ARTERIOESCLEROTICAS, TRATAMIENTOS PARA AFECCIONES ANGIOGENICAS Y OTROS TRASTORNOS PROLIFERATIVOS CELULARES.
ES95933137T 1994-09-16 1995-09-15 Utilizacion de halogenuros aromaticos para tratar la proliferacion de celulas mamarias. Expired - Lifetime ES2190788T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30788794A 1994-09-16 1994-09-16

Publications (1)

Publication Number Publication Date
ES2190788T3 true ES2190788T3 (es) 2003-08-16

Family

ID=23191588

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933137T Expired - Lifetime ES2190788T3 (es) 1994-09-16 1995-09-15 Utilizacion de halogenuros aromaticos para tratar la proliferacion de celulas mamarias.

Country Status (7)

Country Link
EP (1) EP0783303B1 (es)
JP (2) JP4099226B2 (es)
AU (1) AU703863B2 (es)
CA (1) CA2200084C (es)
DE (1) DE69528992T2 (es)
ES (1) ES2190788T3 (es)
WO (1) WO1996008240A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028103A (en) * 1994-09-16 2000-02-22 Children's Medical Center Corporation Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
US7531573B2 (en) * 1994-09-16 2009-05-12 Children's Medical Center Corporation Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
ES2190788T3 (es) * 1994-09-16 2003-08-16 Harvard College Utilizacion de halogenuros aromaticos para tratar la proliferacion de celulas mamarias.
US6992079B2 (en) 1997-11-20 2006-01-31 President Fellows of Harvard College Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6800658B2 (en) 1997-11-20 2004-10-05 Children's Medical Center Corporation Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
IL136225A0 (en) 1997-11-20 2001-05-20 Nuchem Pharmaceuticals Inc Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
WO2000030632A1 (en) * 1998-11-23 2000-06-02 Eisai Co., Ltd. Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
US7300916B2 (en) 2001-02-27 2007-11-27 Yoshiko Yasuda Preventives/remedies for thickened scar, keloid or chronic arthritic diseases
DK1459762T3 (da) 2001-11-02 2008-10-06 Yoshiko Yasuda Anvendelse af EMP9 til forebyggelse af proliferative organsygdomme
EP2305246B1 (en) * 2005-01-31 2015-08-26 The Trustees of the University of Pennsylvania Tumor necrosis factor inhibitors
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
PT2152663E (pt) * 2007-06-04 2014-06-03 Univ Ben Gurion Compostos de triarilo e composições que compreendem os mesmos
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
FR2975911A1 (fr) * 2011-06-06 2012-12-07 Univ Strasbourg Bisacodyl et analogues comme medicaments destines au traitement du cancer
CN115703734B (zh) * 2021-08-05 2024-08-09 重庆文理学院 二芳基甲基吡啶类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0311616B1 (en) * 1986-06-17 1991-09-25 Biogen, Inc. Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
ES2190788T3 (es) * 1994-09-16 2003-08-16 Harvard College Utilizacion de halogenuros aromaticos para tratar la proliferacion de celulas mamarias.

Also Published As

Publication number Publication date
DE69528992T2 (de) 2003-09-18
CA2200084A1 (en) 1996-03-21
JP4099226B2 (ja) 2008-06-11
EP0783303B1 (en) 2002-11-27
AU3590895A (en) 1996-03-29
JP2007277273A (ja) 2007-10-25
EP0783303A1 (en) 1997-07-16
CA2200084C (en) 2007-03-27
JPH10511080A (ja) 1998-10-27
AU703863B2 (en) 1999-04-01
DE69528992D1 (de) 2003-01-09
WO1996008240A1 (en) 1996-03-21

Similar Documents

Publication Publication Date Title
ES2156934T3 (es) Compuestos que presentan una potente actividad de antagonistas del calcio y de antioxidantes y su utilizacion como agentes citoprotectores.
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
YU64701A (sh) Jedinjenja upotrebljiva kao anti-inflamatorna sredstva
ECSP066362A (es) Inhibidores de quinesina mitótica.
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
ES2176600T3 (es) Derivado de la propiofenona y procedimientos para su preparacion.
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
NI200500087A (es) Derivados 4-tetrazolyl-4 fenilpiperidina para el tratamiento del dolor
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
CR8823A (es) Metodos y composiciones para la cicatrizacion de heridas
ATE448207T1 (de) Mitotische kinesin-hemmer
UY27169A1 (es) Derivados del ácido isoftálico como inhibidores de metalproteinasas de la matriz
MX9705569A (es) Inhibidores de adhesion celular.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
NO20050198L (no) Mitotiske kinesininhibitorer
ES2144980T1 (es) Metodos y composiciones para tratar la rinitis alergica y otros trastornos, empleando descarboetoxiloratadina.
AR016751A1 (es) Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
DK1742644T3 (da) Terapeutisk sammensætning indeholdende mindst et pyrrolbenzodiazepin-derivat og fludarabin
SV2009003330A (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
AR083205A1 (es) Metodo para tratar el crecimiento celular anomalo
UY26889A1 (es) Compuestos farmacéuticos
BR0015392A (pt) Lipoxina a4 e seus análogos para o tratamento de olho ressecado
ES2164899T3 (es) Uso de alcaloides de la clase lamellarina en metodos de tratamiento.